OPDP Regulatory Information
Laws, Regulations, Guidances, and Compliance Actions
Some of the links from this page take you to other government web sites. Once you leave this page, click the back button on your browser to return to OPDP's web site.
Federal Food, Drug and Cosmetic Act
- Chapter II - Definitions (Sec. 201 [321] (g)(1), (k), (m), (n), & (p))
- Chapter III - Prohibited Acts and Penalties (Secs. 301 [331], 302 [332], 303 [333], & 304 [334])
- Chapter V - Drugs and Devices (Sec. 502. [352] (a), (e), (f), & (n))
Code of Federal Regulations
The following links go to the Government Printing Office web site.
- 21 CFR 200 - General (Secs. 5, 7, & 200)
- 21 CFR 201 - Labeling Secs. 10, 100, & 200)
- 21 CFR 202 - Prescription Drug Advertising
- 21 CFR 312 - Investigational New Drug Application (Sec. 7)
- 21 CFR 314 - Applications to Market New Drug or Antibiotic (Secs. 81, 550, & 560)
Guidances
- Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers *DRAFT* (Issued 10/23/2023. Posted 10/24/2023)
- Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer (DTC) Promotional Labeling and Advertisements *FINAL* (Issued 6/27/2023. Posted 6/28/2023)
- Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products--Questions and Answers *DRAFT* (Issued 2/3/2020. Posted 2/4/2020)
- Providing Regulatory Submissions in Electronic and Non-Electronic Format - Promotional Labeling and Advertising Materials for Human Prescription Drugs *REVISED FINAL* (Posted 4/11/2022)
- Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers *FINAL* (Issued 6/12/2018, Updated Post 9/28/2021)
- Medical Product Communications that Are Consistent With the FDA-Required Labeling – Questions and Answers *FINAL* (Issued 6/12/2018, Updated, Posted 9/28/2021)
- Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling *FINAL* (Issued 12/11/2017, Posted 12/12/2017)
- Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs *REVISED DRAFT* (Posted 8/5/2015)
- Internet/Social Media Platforms with Character Space Limitations - Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices *DRAFT* (Posted 6/17/2014)
- Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices *DRAFT* (Posted 6/17/2014)
- Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics *DRAFT* (Posted 1/14/2014)
- Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices *DRAFT* (Posted 12/27/2011)
- Presenting Risk Information in Prescription Drug and Medical Device Promotion *DRAFT* (Posted 5/27/2009)
- Consumer-Directed Broadcast Advertisements *FINAL* (issued 8/1999, posted 8/6/1999)
- Industry-Supported Scientific and Educational Activities *FINAL* (Issued 12/3/1997, Posted 12/4/1997)
Compliance Actions
1997-2016 Compliance Actions are archived. To view them, please see the FDA Archive.
Resources For You
Return to the Office of Prescription Drug Promotion (OPDP)